Document Detail

M14K and M38K malignant pleural mesothelioma cell lines preserve the same claudin-based phenotype in vivo.
MedLine Citation:
PMID:  23422483     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Malignant pleural mesothelioma (MPM) is an aggressive neoplasm with few treatment options. Reliable tumour cell lines for mesothelioma research are rare. Claudins seem to be attractive targets for cancer therapy.
AIM: To establish a claudin-based MPM phenotype and to verify whether it is preserved in vitro and in vivo.
MATERIALS AND METHODS: Claudin-3 and -4 expression was examined by immunohistochemistry and immunoblotting in MPM (n=15) and lung adenocarcinoma (n=5) specimens. Claudin-3, -4 and -15 expression was also assessed in MPM versus adenocarcinoma cell lines and in MPM versus adenocarcinoma-derived tumour xenografts mouse models.
RESULTS: A defined MPM phenotype was established: M14K and M38K cell lines highly express Claudin-15 and calretinin but not claudin-3 nor claudin-4. Similar results were obtained in xenograft mouse models.
CONCLUSION: M14K and M38K cell lines, whether in vitro or in an animal model are representative models and appropriate in exploring new therapeutic strategies in MPM that may target claudins.
Siham Chaouche-Mazouni; Marie-Christine Copin; Philippe Lassalle; Nemcha Lebaili; Alexis Cortot; Arnaud Scherpereel
Related Documents :
25128483 - Mir-27a regulates cisplatin resistance and metastasis by targeting rkip in human lung a...
24476153 - Osmotic stress and recovery in field populations of zygnema sp. (zygnematophyceae, stre...
1070153 - Ultrastructural studies of rabbit synovitis induced by autologous igg fragments. i. pro...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  In vivo (Athens, Greece)     Volume:  27     ISSN:  1791-7549     ISO Abbreviation:  In Vivo     Publication Date:    2013 Mar-Apr
Date Detail:
Created Date:  2013-02-20     Completed Date:  2013-08-22     Revised Date:  2014-07-31    
Medline Journal Info:
Nlm Unique ID:  8806809     Medline TA:  In Vivo     Country:  Greece    
Other Details:
Languages:  eng     Pagination:  227-32     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adenocarcinoma / drug therapy,  metabolism*,  pathology
Calbindin 2
Cell Line, Tumor
Claudins / metabolism*
Lung Neoplasms / drug therapy,  metabolism*,  pathology
Mesothelioma / drug therapy,  metabolism*,  pathology
Mice, SCID
Molecular Targeted Therapy
Neoplasms, Experimental / drug therapy,  metabolism*,  pathology
Pleural Neoplasms / drug therapy,  metabolism*,  pathology
S100 Calcium Binding Protein G / metabolism
Xenograft Model Antitumor Assays
Reg. No./Substance:
0/CALB2 protein, human; 0/Calb2 protein, mouse; 0/Calbindin 2; 0/Claudins; 0/S100 Calcium Binding Protein G

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Pulmonary epithelioid haemangioendothelioma studies in vitro and in vivo: new diagnostic and treatme...
Next Document:  Changes of metabolic profiles in an oral squamous cell carcinoma cell line induced by eugenol.